Evolus, Inc.

NASDAQ:EOLS

Drug Manufacturers - Specialty & Generic

Healthcare
$7.07 -2.00%

-$0.14 today

Market cap
$467.95M
Beta
1.33
P/E (TTM)
-9.9
EPS (TTM)
-$0.67
52W Low $3.86High $10.20

Volume 0.80M

Average 0.86M

EOLS Income Before Tax

Profit after all operating and non-operating items but before income tax.

Evolus, Inc.NASDAQ: EOLS

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$10.42M, compared with -$18.82M a year earlier. Trailing-twelve-month income before tax was -$42.56M.

Context

  • Income before tax amounted to 17.1% of revenue in FY2025, down 1.5 pp from a year earlier.
  • Income before tax grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$10.42M or moves back toward the trailing-twelve-month quarterly average of -$10.64M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$10.42M-2122.9% QoQ
Last fiscal yearDec 2025
-$50.96M-2.4% YoY
LTMMar 2026
-$42.56M+23.3% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+44.6%——
1 year-2.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(50.96M) USD
Year-over-year change
-2.4%

Income Before Tax vs competitors

How EOLS compares with its peers on the latest reported figures

No competitor Income Before Tax figures are available to compare.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue99.67M148.62M202.09M266.27M297.18M
Cost of Revenue43.53M58.84M61.56M83.97M104.41M
Gross Profit56.14M89.77M140.53M182.3M192.76M
Gross Margin56.3%60.4%69.5%68.5%64.9%
Research & Development2.06M6.74M15.43M9.17M9.58M
Selling, General & Admin112.07M141.84M164.94M198.03M220.79M
Operating Expenses100.54M155.1M189.76M216.72M230.36M
Depreciation & Amortization6.31M3.72M5.87M6.02M8.74M
EBITDA(39.06M)(53.85M)(41.81M)(25M)(22.53M)
EBITDA Margin-39.2%-36.2%-20.7%-9.4%-7.6%
Operating Income(44.41M)(65.33M)(49.23M)(34.41M)(37.6M)
Operating Margin-44.6%-44.0%-24.4%-12.9%-12.7%
Interest Income1K119K860K3.26M1.93M
Interest Expense1.4M9.1M13.83M18.74M19.69M
Other Income / Expenses(2.36M)(8.99M)(12.28M)(15.35M)(13.36M)
Income Before Tax(46.77M)(74.32M)(61.51M)(49.76M)(50.96M)
Pre-Tax Margin-46.9%-50.0%-30.4%-18.7%-17.1%
Income Tax Expense42K95K176K664K677K
Net Income(46.81M)(74.41M)(61.69M)(50.42M)(51.64M)
Net Margin-47.0%-50.1%-30.5%-18.9%-17.4%
EPS (Basic)(0.94)(1.33)(1.08)(0.81)(0.80)
EPS (Diluted)(0.94)(1.33)(1.08)(0.81)(0.80)
Weighted Avg Shares49.77M56.07M56.92M62.02M64.47M
Weighted Avg Shares (Diluted)49.77M56.07M56.92M62.02M64.47M

Evolus, Inc.

NASDAQ:EOLS

Intrinsic Alpha fair value

Locked

Current Price

$7.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.